Kailera Secures $600M to Advance Dual-Targeting Obesity Drug to Global Phase 3 Tests

Bain Capital Private Equity led Kailera Therapeutics’ Series B financing, which will support global Phase 3 tests of KAI-9531, a weekly injectable drug that hits the same targets as Eli Lilly’s blockbuster obesity medication, Zepbound. The capital will also support development of other oral and injectable metabolic medicines in Kailera’s pipeline. The post Kailera Secures…

Read More

Why Brittle Bones Aren’t Just a Woman’s Problem

Ronald Klein was biking around his neighborhood in North Wales, Pennsylvania, in 2006 and tried to jump a curb. “But I was going too slow — I didn’t have enough momentum,” he recalled. As the bike toppled, he thrust out his left arm to break the fall. It didn’t seem like a serious accident, yet…

Read More